Skip to main content
SpringerLink
Log in

Liraglutide is an effective drug for the treatment of obesity also in real life

  • Comment
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ferrari F, Fierabracci P, Salvetti G, Jaccheri R, Vitti J, Scartabelli G, Meola A, Magno S, Ceccarini G, Santini F (2020) Weight loss effect of Liraglutide in real-life: the experience of a single Italian obesity center. J Endocrinol Invest. https://doi.org/10.1007/s40618-020-01334-1

    Article  Google Scholar 

  2. Wharton S, Liu A, Pakseresht A, Nørtoft E, Haase CL, Mancini J, Power GS, Vanderlie S, Christensen RAG (2019) Real-world clinical effectiveness of Liraglutide 3.0 mg for weight management in Canada. Obesity 27:917–924. https://doi.org/10.1002/oby.22462

    Article  CAS  Google Scholar 

  3. Gorgojo-Martinez JJ, Basagoiti-Carreño B, Sanz-Velasco A, Serrano-Moreno C, Almodóvar-Ruiz F (2019) Effectiveness and tolerability of Orlistat and Liraglutide in patients with obesity in a real-world setting: the XENSOR study. Int J Clin Pract 73:e13399. https://doi.org/10.1111/ijcp.13399

    Article  CAS  PubMed  Google Scholar 

  4. Maccora C, Ciuoli C, Goracci A, Benenati N, Formichi C, Pilli T, Verdino V, Mnutr ON, Bufano A, Tirone A, Voglino C, Fagiolini A, Castagna MG (2020) One month weight loss predicts the efficacy of Liraglutide in obese patients: data from a single center. Endocr Pract 26:235–240. https://doi.org/10.4158/EP-2019-0169

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine and Surgery, Endocrine Unit, University of Insubria, ASST dei Sette Laghi, Ospedale di Circolo, Viale Borri, 57, Varese, Italy

    E. Piantanida, D. Gallo & M. L. Tanda

Authors
  1. E. Piantanida
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Gallo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. L. Tanda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. Piantanida.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This manuscript does not contain original research either on animal or on human subjects.

Research involving human participants and/or animals

Not applicable.

Informed consent

For this type of study, formal consent is not required.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Piantanida, E., Gallo, D. & Tanda, M.L. Liraglutide is an effective drug for the treatment of obesity also in real life. J Endocrinol Invest 43, 1827–1828 (2020). https://doi.org/10.1007/s40618-020-01348-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40618-020-01348-9

Search

Navigation